RT Journal Article
SR Electronic
T1 Identification of the Human Cytochromes P450 Responsible for in Vitro Formation of <em>R</em>- and <em>S</em>-Norfluoxetine
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1044
OP 1050
VO 297
IS 3
A1 Barbara J. Ring
A1 James A. Eckstein
A1 Jennifer S. Gillespie
A1 Shelly N. Binkley
A1 Mark VandenBranden
A1 Steven A. Wrighton
YR 2001
UL http://jpet.aspetjournals.org/content/297/3/1044.abstract
AB The formation of R- andS-norfluoxetine was analyzed in vitro in human liver microsomes. Low apparent Km values forR-norfluoxetine formation of ≤8 μM andS-norfluoxetine of &lt;0.2 μM were determined.R-Norfluoxetine formation rates in a characterized microsomal bank correlated with the catalytic activities for cytochrome P450 (CYP) 2D6, CYP2C9, and CYP2C8. Expressed CYP2C9, CYP2C19, and CYP2D6 formed R-norfluoxetine following incubation with 1 μM R-fluoxetine and exhibited apparentKm values of 9.7, 8.5, and 1.8 μM, respectively. Multivariate correlation analysis identified CYP2C9 and CYP2D6 as significant regressors with R-norfluoxetine formation. Antibodies to the CYP2C subfamily and CYP2D6 each exhibited moderate inhibition of R-norfluoxetine formation. Therefore, CYP2D6 and CYP2C9 contribute to this biotransformation. At pharmacological concentrations of S-fluoxetine,S-norfluoxetine formation rates in the bank of microsomes were found to correlate only with CYP2D6 catalytic activity and only expressed CYP2D6 was found to be capable of formingS-norfluoxetine. Thus, it would appear that both CYP2D6 and CYP2C9 contribute to the formation ofR-norfluoxetine, whereas only CYP2D6 is responsible for the conversion to S-norfluoxetine. Since the enantiomers of fluoxetine and norfluoxetine are inhibitors of CYP2D6, upon chronic dosing, the CYP2D6-mediated metabolism of the fluoxetine enantiomers would likely be inhibited, resulting in R-norfluoxetine formation being mediated by CYP2C9 and S-norfluoxetine formation being mediated by multiple high Kmenzymes. The American Society for Pharmacology and Experimental Therapeutics